Skip to main content

Treatment-related regret common in localized prostate cancer patients

Upset older man

Around 10% of men with localized prostate cancer experience treatment-related regret but this rate varies by treatment modality and is mediated by posttreatment functional outcomes and patient expectations, study findings indicate.


Excess mortality gap closing, but not for all rheumatic diseases

Chart and magnifying glass

Individuals with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis have almost comparable survival rates to those of the general population, Greek study findings indicate.

Headlines from across medwireNews

26-11-2021 | Diabetes | News | Article

Promising phase 2 results for long-acting amylin analog cagrilintide

The long-acting amylin analog cagrilintide promotes notable weight loss during 26 weeks of use, show phase 2 trial findings.

26-11-2021 | Diabetes | News | Article

Efpeglenatide CV benefits independent of SGLT-2 inhibitor use

The cardiovascular benefits of the GLP-1 receptor agonist efpeglenatide are unrelated to concurrent SGLT2 inhibitor use, suggests an exploratory analysis of AMPLITUDE-O trial data.

26-11-2021 | Rheumatology | News | Article

RESTORE trial suggests no benefit of platelet-rich plasma injections for knee OA

Intra-articular injections of platelet-rich plasma do not reduce knee pain or disease progression for people with symptomatic mild-to-moderate radiographic medial knee osteoarthritis, suggest findings from a randomized controlled trial.

26-11-2021 | Oncology | News | Article

Breast cancer-related vertebral fracture risk characterized

Physicians should be aware of the likelihood of pathologic etiology in advanced breast cancer patients who have sustained fractures of the vertebrae, say US researchers.

25-11-2021 | Rheumatology | News | Article

SLE impacts survival after kidney transplant

A retrospective cohort study shows that patients with systemic lupus erythematosus have similar kidney failure outcomes to non-SLE patients, but a higher risk for death after transplantation.

25-11-2021 | Paediatrics | News | Article

Significant and sustained phase 2 results for maralixibat in Alagille syndrome

The bile acid transport inhibitor maralixibat, given at a higher dose than previously tested, may significantly improve cholestasis in children with Alagille syndrome, shows the phase 2 ICONIC trial.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make your preferred medical news resource.

Meet the team

Image Credits